Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ropivacaine hydrochloride monohydrate
Drug ID BADD_D01969
Description Ropivacaine is an aminoamide local anaesthetic drug commonly marketed by AstraZeneca under the trade name Naropin. It is present as a racemic mixture of the enantiomers containing equal proportions of the “S” and “R” forms. The marketed form contains the single S-enantiomer as the active ingredient.
Indications and Usage Used in obstetric anesthesia and regional anesthesia for surgery.
Marketing Status Prescription; Discontinued
ATC Code N01BB09
DrugBank ID DB00296
KEGG ID D08490
MeSH ID D000077212
PubChem ID 6918111
TTD Drug ID D09RHQ
NDC Product Code 66583-0610; 72375-0004
Synonyms Ropivacaine | 1-Propyl-2',6'-pipecoloxylidide | 1 Propyl 2',6' pipecoloxylidide | Naropin | Ropivacaine Monohydrochloride | Ropivacaine Hydrochloride | AL 381 | AL-381 | AL381 | Naropeine | LEA 103 | LEA-103 | LEA103 | Ropivacaine Monohydrochloride, (S)-isomer
Chemical Information
Molecular Formula C17H29ClN2O2
CAS Registry Number 132112-35-7
SMILES CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.O.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neonatal tachypnoea22.11.01.003; 18.04.09.003--Not Available
Post procedural complication12.02.05.018--Not Available
Breast disorder21.05.04.004--Not Available
Neonatal infection18.04.12.001; 11.01.08.032--Not Available
Respiratory disorder neonatal22.11.01.002; 18.04.09.002--Not Available
Neonatal complications of substance abuse19.07.02.015; 18.04.13.002; 12.03.01.050--Not Available
Infantile vomiting18.04.11.004; 07.01.07.010--Not Available
Anal incontinence17.05.01.021; 07.01.06.029--
The 4th Page    First    Pre   4    Total 4 Pages